Hypermobile Ehlers-Danlos syndrome (hEDS) is a connective tissue disorder that causes joints to move beyond their normal range, along with chronic pain, skin that stretches more than usual, and a wide range of symptoms throughout the body. It is the most common type of Ehlers-Danlos syndrome, with a combined prevalence estimated at about 1 in 500 people. Unlike other forms of EDS, hEDS has no identified genetic marker, so diagnosis depends entirely on clinical evaluation rather than a lab test.
How hEDS Affects the Body
Connective tissue acts like the scaffolding that holds your body together. It’s in your joints, skin, blood vessels, and organs. In hEDS, that scaffolding is structurally weaker than it should be, which creates problems far beyond “being flexible.”
The most recognizable feature is joint hypermobility: joints that bend further than normal, often accompanied by frequent subluxations (partial dislocations) or full dislocations. But hEDS is a systemic condition, meaning it affects multiple body systems. Skin tends to be unusually soft and stretchy, pulling away from the body more than expected but snapping back when released. Wounds often heal poorly, and scars can appear thin and papery. Some people experience organ-related complications, including pelvic organ prolapse, because the connective tissue supporting internal structures is also weakened.
Why It Causes Chronic Pain
Pain is the dominant symptom for most people with hEDS, and it works through more than one pathway. There’s direct pain from joints that are structurally unstable: inflamed tendons, strained ligaments, and cartilage that wears down faster because joints don’t track properly. This is nociceptive pain, the straightforward kind your body generates at the site of tissue damage.
But many people with hEDS also develop neuropathic pain, which originates in the nervous system itself. Small fiber neuropathy, where the tiny nerve endings in the skin and organs malfunction, is one example. Over time, the nervous system can become sensitized. The brain and spinal cord essentially turn up the volume on pain signals, a process sometimes called “wind-up.” Pain that started as a response to joint instability can persist and amplify long after the original injury has healed. This is why hEDS pain often feels disproportionate to what’s visibly wrong, and why it’s so frequently dismissed by clinicians unfamiliar with the condition.
The Diagnostic Delay Problem
People with hEDS wait an average of 22 years between the onset of symptoms and receiving a diagnosis. Symptoms typically begin around age 9, but the average age at diagnosis is 31. This delay isn’t because the condition is subtle. It’s because hEDS produces such a wide constellation of symptoms (joint pain, fatigue, digestive issues, dizziness, skin problems) that patients often see specialists for each symptom individually without anyone connecting the dots.
Diagnosis currently relies on clinical criteria established in 2017, which evaluate generalized joint hypermobility, musculoskeletal complications, family history, and systemic features like unusually stretchy skin or a history of hernias. A major update to these criteria is expected in December 2026, which will replace the existing framework for all types of EDS. Until then, finding a clinician who is familiar with the current criteria remains one of the biggest barriers to diagnosis.
Genetics: What We Know So Far
Every other type of EDS has an identified gene responsible for it. Hypermobile EDS does not. The HEDGE study, one of the largest genetic research efforts focused on hEDS, has found that no single gene explains the condition. Instead, the findings point to multiple rare genetic variants and complex interactions that likely contribute in different combinations across different people.
A few specific findings from HEDGE are worth noting. Rare variants in the TNXB gene (involved in connective tissue structure) were three to five times more common in people with hEDS than in controls, but still only appeared in about 1% of cases. The KLK15 gene, which had been flagged as a possible link in earlier research, did not show a stronger presence in hEDS participants than in the general population. And MTHFR, despite widespread discussion in online communities, showed no connection to hEDS at all.
The practical result is that there is no genetic test for hEDS. Genetic testing can rule out other types of EDS but cannot confirm hypermobile EDS specifically.
Hormonal Fluctuations and Symptom Flares
Many women with hEDS notice that their symptoms worsen at predictable points in their menstrual cycle. This isn’t coincidental. Progesterone, which peaks in the days to weeks before menstruation, directly increases the flexibility of tendons and ligaments throughout the body. In someone whose connective tissue is already too lax, this hormonal shift can temporarily amplify joint instability, subluxations, and pain. For most women, symptoms begin to improve within days of menstrual onset as progesterone levels drop.
Hormonal contraceptives can complicate this picture. Many contain progestogen (a synthetic form of progesterone), either alone or combined with estrogen, and responses vary widely. Some women find their joint symptoms worsen on certain contraceptives while others notice improvement. Pregnancy, which involves sustained high levels of the hormone relaxin along with progesterone, is another period when hEDS symptoms often intensify significantly.
Who Gets Diagnosed
The overwhelming majority of people diagnosed with hEDS are assigned female at birth, roughly 98% in large surveys. Whether this reflects a true biological difference in prevalence or a diagnostic bias remains debated. Joint hypermobility is more common in women generally, and hormonal influences on connective tissue may make symptoms more apparent. But the extreme skew in diagnosis also suggests that men with the condition are likely being missed, either because their presentation differs or because clinicians don’t consider the diagnosis in male patients as readily.
How hEDS Is Managed
There is no cure for hEDS, and no medication that addresses the underlying connective tissue defect. Management centers on physical therapy, activity modification, and pain management.
Physical therapy for hEDS looks different from standard rehabilitation. The goal is to build strength and proprioception (your body’s sense of where your joints are in space) so that muscles can compensate for ligaments that don’t do their job. Research has shown that specific, low-level stabilization exercises are more effective than general functional exercise. An eight-week program of closed-chain and proprioception exercises has demonstrated significant improvements in both joint stability and pain.
For someone in significant pain, a typical progression starts with static exercises performed within the hypermobile range, then moves to dynamic movements, and eventually adds resistance. Exercises like squats, bridging, single-leg standing, and balance board work build the stabilizing muscles around vulnerable joints. Aquatic exercise, swimming, and deep water running are particularly useful because water reduces stress on joints while providing resistance. Tai Chi, Pilates, and cycling are also recommended for the same reason. Nordic pole walking has shown particular effectiveness as a low-impact functional activity.
High-impact activities require caution. Participation in sport, dance, and physical performance is a documented risk factor for injury in hypermobile individuals, and healing times tend to be slower due to altered connective tissue repair. This doesn’t mean people with hEDS should avoid all activity. Rather, the intensity and type of exercise need to be matched to current muscle strength, with careful attention to whether a new activity increases symptoms or triggers flare-ups.